Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
With
Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Men with metastatic castration-resistant prostate cancer
Progressive disease on androgen deprivation therapy
Patients must agree to continue androgen deprivation therapy with a GnRH agonist/antagonist throughout the study or have had a prior bilateral orchiectomy
ECOG performance score ≤ 1
Estimated life expectancy of ≥ 12 months
You may not be if
Prior cytotoxic chemotherapy, aminoglutethimide, ketoconazole, abiraterone, or enzalutamide for the treatment of prostate cancer
Prior participation in a clinical trial of an investigational agent that inhibits the androgen receptor or androgen synthesis (unless the treatment was placebo)
History of brain metastasis, active leptomeningeal disease or seizure
Severe cardiovascular or hepatic disease
Pituitary or adrenal dysfunction
Clareo Health | Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
